Eli Lilly picks Virginia for $5bn drug manufacturing plant
Eli Lilly has revealed the foremost plans from its new swathe of new drug manufacturing facilities it aims to build …
Post
-
-
VarmX and CSL form alliance for blood coagulation treatment development
VarmX has established a partnership with CSL for the development of VMX-C001, designed to aid in restoring blood coagulation in …
-
GSK plans $30bn investment for R&D in US
GSK has announced an investment of $30bn in the US over the next five years for research and development (R&D) …
-
Reunion Neuroscience expands Series A to $133m after positive trial milestones
The success of Reunion Neuroscience’s lead psychedelic candidate in a postpartum depression (PPD) trial has provided a last minute boost …
-
European Society of Cardiology (ESC) Annual Meeting 2025
The European Society of Cardiology (ESC) Annual Meeting 2025, held from August 29 to September 1 in Madrid, Spain, showcased …
-
Novo Nordisk secures EMA approval for Rybelsus label update
Novo Nordisk has received the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) approval for the …
-
aTyr Pharma stock crashes on Phase III pulmonary sarcoidosis fail
aTyr Pharma shares plunged more than 80% after its Phase III trial in pulmonary sarcoidosis failed to meet its primary …
-
Cadrenal Therapeutics acquires eXIthera’s Factor XIa inhibitors
Cadrenal Therapeutics has acquired eXIthera Pharmaceuticals’ portfolio of Factor XIa inhibitors to expand its offerings in the anticoagulation market. Under the …
-
Novartis returns to Monte Rosa for second time in a year with $5.7bn deal
Novartis has ventured back to Monte Rosa Therapeutics tasked with finding more immune-mediated disease drug candidates, signing a licensing deal …
-
Podcast: How RWD Furthers Understanding of Pregnancy
This podcast explores how real-world data (RWD) fills gaps in understanding maternal and infant health, especially since pregnant individual often …
-
AstraZeneca halts £200m research investment in Cambridge
AstraZeneca has halted its planned £200m ($270m) investment in a research facility in Cambridge, UK, according to reports from Reuters. The …
-
FDA chief blames decades of regulatory failure for misleading pharma ads
The US Food and Drug Administration (FDA) commissioner Martin Makary has described the current state of direct-to-consumer pharmaceutical advertising as …
-
Amneal secures FDA approval for sodium oxybate solution
US-based Amneal Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) for its 500mg/mL sodium oxybate oral …
-
LB Pharmaceuticals tops 2025 biotech IPO list with $285m Nasdaq debut
US-based biotech LB Pharmaceuticals has broken the 2025 biotech initial public offering (IPO) drought – and with style – raising …
-
Podcast: key trials and trends from ESC Congress 2025
Eyes in the pharma and medtech industries are directed to the European Society of Cardiology (ESC) Congress every year to …
